Aceso Life Science Group Limited (HK:0474)
:0474
Top Page
Aceso Life Science Group Limited
(0474)
Select Model
Select Model
Rating:52Neutral
Price Target:
HK$0.11
▼(-8.33% Downside)
Action:ReiteratedDate:11/28/25
The overall score of 52 for Aceso Life Science Group Limited is primarily dragged down by poor financial performance, with severe profitability issues and high leverage posing significant risks. Strong technical momentum provides some uplift, but the negative P/E ratio and lack of dividends limit valuation appeal. Investors should remain cautious due to financial instability despite growth potential.
Positive Factors
Revenue Growth
Aceso's strong revenue growth indicates robust demand for its offerings, enhancing its market position and potential for future expansion.
Negative Factors
High Leverage
High leverage increases financial risk, potentially limiting the company's ability to invest in growth and weather economic downturns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Aceso's strong revenue growth indicates robust demand for its offerings, enhancing its market position and potential for future expansion.
Read all positive factors
Aceso Life Science Group Limited (0474) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.06B
Dividend YieldN/A
Average Volume (3M)71.25M
Price to Earnings (P/E)0.3
Beta (1Y)0.18
Revenue Growth-64.04%
EPS Growth1.66%
CountryHK
Employees146
SectorIndustrials
Sector Strength72
IndustryConglomerates
Share Statistics
EPS (TTM)0.05
Shares Outstanding8,858,127,000
10 Day Avg. Volume32,027,675
30 Day Avg. Volume71,252,001
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)30.59
Price to Sales (P/S)1.88
P/FCF Ratio24.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aceso Life Science Group Limited Business Overview & Revenue Model
Company Description
Aceso Life Science Group Limited, an investment holding company, engages in money lending, securities investment, asset management, rental, and trading of construction machinery, repair and maintenance and transportation service, property leasing ...
How the Company Makes Money
Aceso Life Science Group Limited generates revenue primarily through the development and commercialization of its proprietary pharmaceuticals. The company's revenue model includes income from product sales, licensing agreements, and strategic part...
Aceso Life Science Group Limited Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
10
Very Negative
Cash Flow
30
Negative
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 166.00M | 195.00M | 11.00M | 312.00M | 315.00M | 346.00M |
| Gross Profit | 61.00M | 90.00M | -100.00M | 141.00M | 162.00M | 213.00M |
| EBITDA | -210.00M | -860.00M | -220.00M | -21.00M | -359.00M | -69.00M |
| Net Income | -372.00M | -895.00M | -462.00M | -264.00M | -370.00M | -376.00M |
Balance Sheet | ||||||
| Total Assets | 1.72B | 3.24B | 4.79B | 6.30B | 6.26B | 6.17B |
| Cash, Cash Equivalents and Short-Term Investments | 330.00M | 207.00M | 466.00M | 602.00M | 717.00M | 786.00M |
| Total Debt | 1.23B | 2.30B | 2.74B | 2.34B | 3.01B | 2.76B |
| Total Liabilities | 1.35B | 2.50B | 2.97B | 3.73B | 3.44B | 3.15B |
| Stockholders Equity | 371.00M | 12.00M | 921.00M | 1.55B | 2.00B | 2.38B |
Cash Flow | ||||||
| Free Cash Flow | 91.00M | 15.00M | -48.00M | 175.00M | 259.00M | 164.00M |
| Operating Cash Flow | 79.00M | 17.00M | -37.00M | 222.00M | 316.00M | 179.00M |
| Investing Cash Flow | 487.00M | 337.00M | 472.00M | -120.00M | -441.00M | -10.00M |
| Financing Cash Flow | -709.00M | -587.00M | 117.00M | -98.00M | 126.00M | -375.00M |
Aceso Life Science Group Limited Technical Analysis
Neutral
0.12
Price Trends
0.12
Negative
0.12
Positive
0.08
Positive
Market Momentum
>-0.01
Positive
47.43
Neutral
94.74
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0474, the sentiment is Neutral. The current price of 0.12 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.12, and above the 200-day MA of 0.08, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.43 is Neutral, neither overbought nor oversold. The STOCH value of 94.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0474.
Aceso Life Science Group Limited Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
52 Neutral | HK$1.06B | 0.33 | -194.26% | ― | -64.04% | 1.66% | |
51 Neutral | HK$217.00M | -4.81 | -2.33% | 4.00% | 7.98% | -236.14% | |
51 Neutral | HK$1.04B | 19.78 | 3.24% | 2.00% | -54.92% | 26.32% | |
50 Neutral | HK$162.04M | 26.19 | 0.74% | ― | -9.32% | ― | |
49 Neutral | HK$156.97M | -1.81 | -41.80% | ― | -25.59% | 0.69% | |
45 Neutral | HK$158.47M | 2.05 | 7.08% | ― | 9.69% | -33.79% |
* Industrials Sector Average
HK:0474
Aceso Life Science Group Limited
0.12
0.07
140.00%
HK:1063
Suncorp Technologies
0.10
-0.01
-8.85%
HK:0118
Cosmos Machinery Enterprises Limited
0.19
<0.01
4.44%
HK:2182
Tian Chang Group Holdings Ltd.
0.35
-0.03
-7.89%
HK:2327
Meilleure Health International Industry Group Limited
0.26
-0.01
-5.20%
HK:0862
Vision Values Holdings Limited
0.04
0.01
33.33%
Aceso Life Science Group Limited Corporate Events
Aceso Life Science Group Reports Strong Interim Results for 2025
Nov 28, 2025
Aceso Life Science Group Limited announced its interim results for the six months ending September 30, 2025, reporting a significant turnaround with a profit of HK$384 million compared to a loss of HK$195 million in the previous year. The improvem...
Aceso Life Science Group Limited Announces Positive Profit Alert
Nov 25, 2025
Aceso Life Science Group Limited has announced a positive profit alert, expecting to record a profit of approximately HK$380 million for the six months ended 30 September 2025, compared to a loss of HK$195 million in the same period in 2024. This ...
Aceso Life Science Group Schedules Board Meeting for Interim Results
Nov 14, 2025
Aceso Life Science Group Limited has announced a board meeting scheduled for November 28, 2025, to approve and publish the unaudited interim results for the six months ending September 30, 2025. The meeting will also consider the payment of an int...
Aceso Life Science Group Completes Full Loan Repayment
Oct 28, 2025
Aceso Life Science Group Limited has announced the full repayment of a significant outstanding loan amounting to approximately HK$352 million from a commercial bank in Hong Kong. This financial move is likely to positively impact the company’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.